Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Gastric & gastro-oesophageal junction cancer, drawn from the whole corpus: 173 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Peritoneal metastasis.
Background: Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Heterogeneous CLDN18.2/HER2 expression.
Screening only in Japan/Korea.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Peritoneal metastasis is the dominant relapse pattern and is poorly imaged, poorly penetrated by drugs, and excluded from most trials.
Background: Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Diffuse-type and genomically stable tumours lack targets and respond poorly to chemotherapy and immunotherapy.
Nothing recorded yet.
Nothing recorded yet.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
Biomarker overlap (CLDN18.2 with PD-L1) has no randomised guidance on combination versus sequence.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
HER2 and CLDN18.2 expression are heterogeneous and can be lost at progression; re-biopsy or ctDNA before second-line targeting is not standard.
No Western screening strategy; most patients present with advanced disease.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
FGFR2b benefit is uncertain after FORTITUDE-101; the control arm lacked immunotherapy.
Perioperative immunotherapy benefit by PD-L1 or MSI status, and whether chemotherapy can be omitted in MSI-high disease, are unresolved.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 73 changes by month →When this page itself was last checked or edited.
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
Co-primary endpoints including OS met (July 2026); numbers pending.
PFS 12.
A milestone in how this cancer is treated.